GENF vs. POLB, RLM, NSCI, IMM, SNG, OBD, IXI, BVX, FAB, and HEMO
Should you be buying Genflow Biosciences stock or one of its competitors? The main competitors of Genflow Biosciences include Poolbeg Pharma (POLB), Realm Therapeutics (RLM), NetScientific (NSCI), ImmuPharma (IMM), Synairgen (SNG), Oxford BioDynamics (OBD), IXICO (IXI), BiVictriX Therapeutics (BVX), Fusion Antibodies (FAB), and Hemogenyx Pharmaceuticals (HEMO). These companies are all part of the "biotechnology" industry.
Genflow Biosciences vs.
Poolbeg Pharma (LON:POLB) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends.
In the previous week, Poolbeg Pharma's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.
Genflow Biosciences has lower revenue, but higher earnings than Poolbeg Pharma. Genflow Biosciences is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.
Genflow Biosciences has a net margin of 778.46% compared to Poolbeg Pharma's net margin of 0.00%. Poolbeg Pharma's return on equity of -32.56% beat Genflow Biosciences' return on equity.
Poolbeg Pharma has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Comparatively, Genflow Biosciences has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500.
Poolbeg Pharma and Genflow Biosciences both received 0 outperform votes by MarketBeat users.
1.2% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 9.2% of Genflow Biosciences shares are held by institutional investors. 24.7% of Poolbeg Pharma shares are held by company insiders. Comparatively, 64.2% of Genflow Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Genflow Biosciences beats Poolbeg Pharma on 6 of the 10 factors compared between the two stocks.
Get Genflow Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genflow Biosciences Competitors List
Related Companies and Tools
This page (LON:GENF) was last updated on 4/24/2025 by MarketBeat.com Staff
Buy GENF Stock Free GENF Stock Alerts